Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label, multicohort, phase II KEYNOTE-158 study (NCT02628067)....

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 40; číslo 7; s. 752
Hlavní autoři:	O'Malley, David M, Bariani, Giovanni Mendonca, Cassier, Philippe A, Marabelle, Aurelien, Hansen, Aaron R, De Jesus Acosta, Ana, Miller, Jr, Wilson H, Safra, Tamar, Italiano, Antoine, Mileshkin, Linda, Xu, Lei, Jin, Fan, Norwood, Kevin, Maio, Michele
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.03.2022
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Biomarkers, Tumor - genetics DNA Mismatch Repair Endometrial Neoplasms - drug therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - pathology Female Follow-Up Studies Humans Microsatellite Instability Middle Aged Non-Randomized Controlled Trials as Topic Prognosis Retrospective Studies Survival Rate
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!